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Identity: Dynamics and Causal Mechanisms
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Precursor cell entry into the T-cell developmental pathway can be divided into two phases by the closure of T-lineage
commitment. As cells decide against the last alternative options to the T-cell fate, they turn on the transcription factor
Bcl11b and silence expression of a group of multipotent progenitor regulatory factors that include hematopoietic transcription
factor PU.1. Functional perturbation tests show that Bcl11b is needed for commitment while PU.1 actively participates in
keeping open access to alternative fates, until it is silenced; however, PU.1 and Bcl11b both contribute positively to T-cell
development. Our recent work reviewed here sheds light on the transcriptional regulatory network that determines the timing
and irreversibility of Bcl11b activation, the ways that Notch signaling from the thymic microenvironment restricts the action of
PU.1 to prevent it from diverting cells to non-T fates, and the target genes that PU.1 still regulates under the influence of Notch
signaling to contribute to T-cell generation. We argue that T-cell development depends on the sequential operation of two
interlaced, but mutually antagonistic, gene regulatory networks, one initially supporting expansion before commitment and
the other imposing a “terminal” differentiation process on committed cells.
Stem cells are defined by the combination of self-re-
newal capability with multipotentiality (i.e., the sustained
ability to give rise to multiple different types of descen-
dant cells). A corollary of this definition is that when stem
cells generate any particular cell type, the differentiating
intermediates need to make two decisions: one to termi-
nate self-renewal and the other to select the particular
developmental program to activate while suppressing all
of the other alternatives. Understanding of how these two
qualitatively different decisions are intertwined is still
incomplete. Although a great deal is known about how
transcription factors collaborate positively to drive partic-
ular sets of target genes, giving cells a specific function, it
remains much less clear how cells make a clean and co-
herent break with the other possible programs that were
originally available to their precursors. Even less is known
about how cells give up the intrinsic capacity for self-
renewal and replace it with a more restricted and often
limited kind of cell cycle control. One of the best systems
available for shedding light on these questions, however,
is T-cell development in mice.
The early stages of murine T-cell development in which
cells actually choose the T-cell fate are unusually well
defined, since the hematopoietic progenitors that will gen-
erate T cells first migrate to the thymus before making the
fate decision. They thus separate themselves physically
from the immature blood precursors generating other he-
matopoietic cell types, and they do this at a very early
stage of differentiation when they are still multipotent.
Most of the events involved in sequential exclusion of
alternative fates consequently take place within the thy-
mus and can be resolved hierarchically by separating the
precursors based on multiparameter flow cytometry.
Meanwhile, the early T-cell development process itself
has become accessible to monitoring and manipulation
ex vivo by the development of powerful stromal coculture
systems, in which the cells develop with high cloning
efficiency and high clonal expansion, and in which devel-
opment can be started, interrupted for manipulation, and
restarted again. The molecular biology of cells at succes-
sive stages can thus be correlated prospectively with their
developmental potentials, and stage-specific gain and loss
of function manipulations that are possible in this system
have begun to take the machinery of the commitment
process apart.
STEM CELL FATE DETERMINATION
BY NOTCH SIGNALS: PROCESS
AND QUESTIONS
Stem or progenitor cell choice of the T-cell fate is
completely dependent on environmental signals from
Notch–Delta interaction (for recent reviews, see Radtke
et al. 2010; Yuan et al. 2010; Naito et al. 2011; Thompson
and Zu´n˜iga-Pflu¨cker 2011). Progenitor cells cannot
develop into T cells unless they express Notch1, and Del-
ta-like 4 (DLL4) is one of the most important features
of the thymic microenvironment to drive cells into the
T-cell pathway. Notch–Delta interaction is a well-known
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inductive signal that operates in many developmental sys-
tems to trigger a rapid cascade of differentiative conse-
quences. However, what is known about the T-cell
program shows that Notch cannot be the only transcrip-
tional input to establish the T-cell fate. The cells need to
progress through at least four distinct stages, all under the
influence of Notch–Delta signals, with loss of T-cell
identity or loss of viability if the signal is interrupted at
any stage (Fig. 1, top). The population dynamics along
this pathway imply that the progression from stage to stage
is slow, with multiple cell cycles under the influence of
Notch signals at each stage. Direct Notch target genes are
a part of the T-cell differentiation program, as revealed by
RNA expression analysis of cells in which Notch signal-
ing is suddenly interrupted by drug treatment or a switch
to a Delta-free microenvironment. However, although
Notch-dependent T-cell genes are well defined, they are
not the same genes at each stage. In fact, some of the
strongest Notch target genes are expressed primarily at
the beginning of the process, such as Nrarp; others such
as Il2ra and HEBalt are activated abruptly in the middle;
whereas others such as Ptcra are expressed very preferen-
tially toward the end. Finally, lineage commitment does
not occur until after at least two phenotypic stage transi-
tions and numerous cell cycles under the influence of
Notch–Delta. The behavior of the cells thus raises three
general questions about how the Notch signal drives T-
cell development. First, why is the lineage commitment so
slow, with step times of days (with 2 cell cycles/d)
rather than hours? Second, why are different Notch target
genes turned on at each step? Third, what makes the se-
quence of these individual steps irreversible?
An obvious general answer is that Notch signals acti-
vate a cascade of transcription factor gene expression
changes, which themselves affect the regulatory states in
which Notch signals are interpreted in each of the succes-
sive stages. In fact, the population of transcription factor
genes that is expressed in the cells at the beginning of the
process is radically different from the population of fac-
tors expressed soon after commitment has occurred. Fig-
ure 1 shows some of the most important transcription
factor gene expression changes during this process (also
see Rothenberg et al. 2010). The cells enter the thymus
with a legacy of stem and progenitor genes closely shared
with those of prethymic common lymphoid precursors
and lymphoid-primed multipotent precursors (Kawazu
et al. 2007; Tydell et al. 2007; David-Fung et al. 2009;
Luc et al. 2012; Zhang et al. 2012; Mingueneau et al.
2013). They initially respond to Notch signals by activat-
ing expression of two transcription factors, GATA-3 and
TCF-1 (encoded by the Tcf7 gene) within the first major
stage, the ETP (or Kit-high DN1) stage (Fig. 1). This then
creates a new state that we have referred to as “phase 1” of
T-cell development, in which T-cell transcription factors
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Figure 1. Outline of early T-cell development. (Top) Succession of early intrathymic developmental stages referred to in the text.
LMPP, lymphoid-primed multipotent precursor; CLP, common lymphoid precursor; DN, CD42 CD82 surface TCR2; ETP (Kit-high
DN1), Kithigh CD44high CD252 DN; DN2a, Kithigh CD44high CD25þ DN; DN2b, Kitint/þ CD44high CD25þ DN; DN3a, Kitlow
CD44low CD25þ DN; DP, CD4þ CD8þ TCRb1. Blue arrows depict continuous requirement for Notch signaling from ETP through
DN3a stage, despite substantial regulatory changes throughout these stages. Curved reflex arrows depict phases of proliferation, either
self-renewal or “transit amplifying” type. (Lower panel) Schematic depicting expression patterns (impressionistic log scale, arbitrary
units) of three T-lineage transcription factors, GATA-3, TCF-1, and Bcl11b, one pan-hematopoietic transcription factor Runx1/CBFb,
and the multilineage transcription factor PU.1. Other phase 1 transcription factors are regulated similarly to PU.1 (see Fig. 2, Table 1).
(Figure adapted from Rothenberg 2012.)
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overlap substantially with a population of progenitor fac-
tors that are still being expressed (Rothenberg et al. 2010).
Notch signaling in the new context turns on additional
genes, marking the transition to the DN2a stage, yet
even so the cells remain uncommitted. Commitment is
only completed as the cells progress from DN2a to
DN2b stage, and this event is accompanied by two distinct
types of regulatory change. The regulatory gene Bcl11b
turns on, followed soon after by Lef1, Ets1, and Ets2; and
the stem- and progenitor-associated factors are concomi-
tantly turned off. Transcription factor genes turned off in
this period include Sfpi1 (coding for PU.1), Tal1 (coding
for SCL), Hhex, and Gfi1b, with Lyl1 turned off one stage
later (Yui et al. 2010). This transition now establishes the
main outlines of the regulatory state that will persist as the
cells stop dividing, undergo TCR gene rearrangement, and
embark on their first TCR-dependent selection event,
b-selection.
The reciprocal changes in expression of PU.1 and
Bcl11b during commitment are particularly dramatic.
Figure 2 (main graph) shows that the fold changes in ex-
pression of the genes encoding these two factors, between
the ETP (Kitþ DN1) and newly committed DN2b stages,
are at the extremes for all transcriptional regulatory genes
in the genome (Zhang et al. 2012).Bcl11b is one of the two
most strongly up-regulated, whereas PU.1 (Sfpi1) is one of
the six most strongly down-regulated. As summarized in
the inset of Figure 2, our work with a fluorescent reporter
allele of Bcl11b shows that it in fact turns on in individual
cells at the end of the DN2a stage, immediately before the
cells make the transition to commitment (Rothenberg et al.
2008; Yui et al. 2010; Zhang et al. 2012; HY Kueh,
unpubl.). PU.1 begins and remains at maximal levels
through the DN2a stage, then begins a sharp decline during
commitment, although the last residual vestiges of expres-
sion are still detectable in DN3a cells (Yui et al. 2010).
Both factors are not only regulated in the course of com-
mitment but also functionally implicated in the T-cell
lineage commitment mechanism, as described below (An-
derson et al. 2002; Dionne et al. 2005; Lefebvre et al. 2005;
Franco et al. 2006; Laiosa et al. 2006; Masuda et al. 2007;
Ikawa et al. 2010; Li et al. 2010a,b). Central questions
about the nature and timing of the T-lineage commitment
process can therefore be investigated in terms of two
discrete problems: why it takes so long for Bcl11b to be
turned on, and what PU.1 (and other “phase 1” factors) is
doing in the T-lineage progenitor cells until it is turned off.
COMMITMENT AND THE ROLE OF Bcl11b
Commitment is a multistep process that begins even
before the cells enter the thymus. The final step of com-
mitment that is coupled with changes in Bcl11b and PU.1
expression is specifically the loss of access to the last two
alternative pathways: the natural killer (NK) cell pathway,
and the dendritic cell (DC) or myeloid pathway. The
cells have lost access to the B-cell developmental option
many cell cycles earlier, through a separate mechanism
triggered as a result of GATA-3 induction (Garcı´a-Ojeda
et al. 2013; DD Scripture-Adams, L Li, AM Arias, et al.,
unpubl.). The NK and DC/myeloid pathways are molec-
ularly dissimilar, and most likely are independently con-
trolled. However, what they have in common is that they
are able to be blocked in an ongoing way by environmental
Notch signaling, even though they are still available to
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Figure 2.Transcription factors that change expression during commitment. Main panel: Genes encoding transcriptional regulators that
change most in expression between ETP/DN1 stage and newly committed DN2b stage, with fold changes measured by genome-wide
RNA sequencing (RNA-seq) analysis (Zhang et al. 2012). Genes annotated as regulatory genes with largest fold decreases in
expression or increases in expression (DN2b/DN1 levels ,0.5 or .2, FDR ,0.05) are arranged on x-axis in the order of fold
change. Values on y-axis are log2-transformed ratios of (expression in DN1)/(expression in DN2b). Axis order is set to show down-
regulated genes below the x-axis and up-regulated genes above the x-axis. PU.1 (Sfpi1) and Bcl11b are highlighted by red labels. Inset:
Schematic depiction of expression pattern of Bcl11b as defined at the single-cell level by expression of a Bcl11b-IRES-mCitrine
fluorescent protein reporter allele described in text (HY Kueh and EV Rothenberg, unpubl.).
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PU.1-expressing, Bcl11b-negative DN2a cells if Notch
signaling is withdrawn (Balciunaite et al. 2005; Masuda
et al. 2007; Bell and Bhandoola 2008; Wada et al. 2008;
Yui et al. 2010). Only as cells turn on Bcl11b and turn off
PU.1 do they lose access to both alternatives uncondition-
ally, whether Notch signals are present or not. One feature
that makes the transition abrupt is that the cells lose the
ability to survive in the absence of Notch signals. They
thus become addicted to conditions that block NK, DC,
and myeloid development alike. The cells remain Notch
dependent thereafter until they can express a productive
pre-TCR or gdTCR complex.
Bcl11b action is directly required for this step of
T-lineage commitment (Ikawa et al. 2010; Li et al.
2010a, b). If the Bcl11b gene is deleted, progenitors can
still develop in response to Notch–Delta signals all the
way to the DN2a stage, but then progression is arrested.
The cells turn on the earliest sets of T-cell genes but fail to
switch completely to the transcriptional program that
characterizes the DN2b/DN3a state (Li et al. 2010a). Im-
portantly, cells that have developed to this stage with am-
ple Notch and cytokine signaling do not die without
Bcl11b; instead, they can keep proliferating as DN2a-
like cells as long as these signals are provided. If Notch
signaling becomes limiting, however, they rapidly tend to
switch to an NK cell–like fate (Li et al. 2010a, b). Fur-
thermore, cells that have developed without Bcl11b do not
give up their access to myeloid fates, as can be seen if a
different set of supportive cytokines is provided (Ikawa
et al. 2010; Li et al. 2010a). By comparing the effects of
Bcl11b deletion from the start of T-cell development with
the effects ofBcl11b removal at the DN3a stage, it appears
that Bcl11b may play two different roles (L Li, JA Zhang,
and EV Rothenberg, unpubl.). In one role, it is a direct,
continuously required repressor of NK and NKT-like
functions (Li et al. 2010b), apparently with the ability to
repress the NK-cell regulator Id2 directly (Kastner et al.
2010) (Fig. 3). In the other role, it is an indispensable
component required for a hit-and-run process of DN2a
to DN2b progression, which excludes myeloid lineage
fates, a role that is correlated with the eventual silencing
of Sfpi1 and many other phase 1 genes (Ikawa et al. 2010;
Li et al. 2010a) (L Li, JA Zhang, and EV Rothenberg,
unpubl.).
GENE NETWORK REQUIREMENTS
FOR COMMITMENT PROBED THROUGH
Bcl11b REGULATION
Commitment thus depends on fulfilling the regulatory
requirements for inducing Bcl11b. This is a process that
involves active removal of epigenetic silencing marks,
since the Bcl11b gene begins with strong CpG methyla-
tion at multiple regulatory sites (Ji et al. 2010) and histone
H3K27me3 modifications persisting all the way into the
DN2a stage (Zhang et al. 2012; Li et al. 2013). Both are
removed as the cells turn the gene on. One required input is
Notch. Bcl11b expression is activated only in cells that
have been exposed to Notch signaling, and there are clear
binding sites for Notch/RBPJ around its promoter and
50 introns (Li et al. 2010b). However, Notch/RBPJ is
not the only transcription factor controlling its induction.
Once induced, Bcl11b expression persists even when
Notch signals are removed (Del Real and Rothenberg
2013; HY Kueh, MA Yui, and EV Rothenberg, unpubl.).
Starting from purified DN2a cells that have not yet turned
on Bcl11b expression, we have tested the effects of Notch
ligand density on Bcl11b activation in individual cells
with a Bcl11b-IRES-fluorescent protein reporter. Quanti-
tative analysis of this system shows that the intensity of
Notch–Delta signals affects the frequency of cells turning
on Bcl11b much more than it affects the level of Bcl11b
expression per cell (HY Kueh, MA Yui, and EV Rothen-
berg, unpubl.). Thus, Notch signals may be mostly per-
missive; other factors must drive the magnitude of actual
transcriptional activity. This conclusion actually agrees
well with the long period of Notch signaling required
before the Bcl11b gene is turned on. Additional factors
that are genetically implicated through gain or loss of
function experiments include Runx/CBFb (Guo et al.
2008), GATA-3 (Garcı´a-Ojeda et al. 2013), and TCF-1
(Weber et al. 2011).
Validating the roles of these inputs depends on identi-
fication of concrete protein–DNA interactions needed for
regulation. The promoter-proximal region of Bcl11b is
not sufficient to drive T-lineage-specific expression of a
reporter in transfected cells: Its expression is similar in
pro-T and myeloid cell lines (Li et al. 2013). To look for
additional regulatory elements, therefore, we have recent-
ly used a strategy based on tracking changes in the status of
histone marks during the stages when Bcl11b is first
turned on, scanning a region on the order of 2 Mb
around the Bcl11b gene. In a gene desert more than
800 kb downstream from Bcl11b, we located a region
that shifted from repressive to active histone marks across
the same developmental interval in which this occurred at
Delta
RunxE proteins
Notch
Bcl11b
Id2
Il2ra (CD25)Cd3g,d,ePtcra
Gata3
Tcf7 (TCF-1)
Figure 3. Feed-forward motifs in a gene regulatory network
model for T-cell specification. Schematic shows a partial gene
regulatory network contributing to the activation and impact of
Bcl11b expression. Solid lines: Experimental evidence for reg-
ulatory impact and direct binding. Dashed lines: Evidence for
direct binding, possible but not yet proven function at those sites.
Dotted lines: Evidence for functional effect.
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the Bcl11b promoter, and we found evidence by chroma-
tin conformation capture experiments that this marked
region loops to the Bcl11b promoter/first intron region
in a T-lineage-specific way (Li et al. 2013). This region
has T-lineage cis-regulatory activity in a variety of assays,
cooperating specifically with sequences near the Bcl11b
promoter and first intron. In a stable transfection system
where even a Bcl11b locus bacterial artificial chromo-
some construct spanning tens of kilobases upstream of
and downstream from the gene fails to give expression,
addition of the far-distal cis-regulatory element is suffi-
cient to confer T-lineage-specific expression. This pro-
vides a system in which specific transcription factor–
target site interactions can be tested for direct causal roles
in Bcl11b regulation. In fact, Runx1 and TCF-1 not only
bind to activation-marked sites in the first intron and up-
stream of the Bcl11b promoter, but also in this far-down-
stream cis-regulatory element. In the far-distal element,
both a TCF-1/Runx-binding site cluster and a second pair
of TCF-1-binding sites are functionally important (Li
et al. 2013). GATA-3 may also exert its effects through
this element, which it binds weakly, or through additional
distal cis-regulatory elements that remain to be character-
ized. The evidence thus provides good support for a feed-
forward network circuit in which not only Notch signals,
but also products of the Notch-induced factors TCF-1
(Tcf7) and probably GATA-3 as well, together play essen-
tial roles in opening up Bcl11b for expression (Fig. 3).
PHASE 1 REGULATORY GENES AND THE
NEED FOR REPRESSION
The elaborate machinery that seems to be needed to turn
on Bcl11b begs the question of what the cells are doing
through all the cell cycles they traverse before they under-
go commitment. The best estimate we have been able to
calculate, using the in vivo repopulation data reported by
Petrie and coworkers (Porritt et al. 2003), is that at least 10
cell cycles elapse between the time of thymus-settling
precursor entry into the thymus of a postnatal mouse and
the commitment step when cells turn onBcl11b (Manesso
et al. 2013). In the meantime, the uncommitted ETP and
DN2a cells, as purified ex vivo or from in vitro differen-
tiation cultures, are consistently found to express a large
set of regulatory genes associated with non-T alternative-
lineage differentiation, stem cell self-renewal, and/or T-
cell leukemogenesis (Table 1) (Tabrizifard et al. 2004;
Kawazu et al. 2007; Tydell et al. 2007; David-Fung
et al. 2009; McCormack et al. 2010; Belyaev et al. 2012;
Zhang et al. 2012; Mingueneau et al. 2013). Any concern
that this gene expression pattern might just reflect the
difficulty of purifying these early cells away from alter-
native-lineage contaminants is greatly reduced by finding
that the expression of these genes can indeed be stable in
cells with early T-lineage markers. Bcl11b-knockout
cells, even after repeated sorting for DN2a phenotype
and propagation for weeks in culture, continue to express
these genes. In cells with normal Bcl11b function, analy-
sis of developing T-lineage cells with dual fluorescent
reporters for PU.1 and Bcl11b shows that the same cells
that turn on Bcl11b are also initially expressing high levels
of PU.1 (HY Kueh, unpubl.). Thus until Bcl11b can be
activated, the expression of these stem/progenitor genes
demarcates a sustainable “phase 1” part of the T-cell de-
velopment program.
It is obvious that the phase 1 genes must be repressed in
normal T-cell development. Aberrant later activity of
genes like Tal1, Lyl1, and Lmo2 is a major contributor
to T-cell malignancy, whereas Erg, Hhex, Mef2c, and
Sfpi1 deregulation can also promote malignancy (Palo-
mero et al. 2006; Rosenbauer et al. 2006; Zhong et al.
2007; McCormack et al. 2010; Tremblay et al. 2010;
Homminga et al. 2011; Thoms et al. 2011). Failure of cells
to repress phase 1 genes completely in the DN3 stage,
before activating genes associated with b-selection, also
appears to underlie a spontaneous high-penetrance T-cell
malignancy that we have recently described in NOD back-
ground thymocytes (Yui et al. 2013). Moreover, it appears
that more than one repressive switch mechanism needs to
be used in a coordinated way to ensure normal develop-
ment. The phase 1 genes vary substantially in the fine-
scale timing of their repression and in the degrees to which
H3K27me3 repressive marks need to be deposited by
Polycomb Repressive Complex 2 to keep them off (Zhang
et al. 2012). In the case of PU.1, something is known about
the repression machinery that normally silences it, even
though PU.1 remains unmarked with H3K27me3. Runx
family transcription factors switch from being activators
of PU.1 expression to repressors (Huang et al. 2008). At
least in part this is because they become engaged at a
T-lineage-specific silencer element that may quench the
activation effects of the major Sfpi1 enhancer (Zarnegar
et al. 2010; Zarnegar and Rothenberg 2012). It is tempting
Table 1. “Phase 1” transcription factors maintained in early
T-lineage cells
Characteristic Genes
Expressed until mid ETP stagea Meis1, Lmo2, Mef2c, and
Hoxa9 (transcription
factors)
Flt3 (growth factor receptor)
Expressed in two phases,
decreasing ETP to DN2a but
not silent until after DN3a
Bcl11a, Erg (transcription
factors)
Expressed in ETP and DN2a,
decreasing sharply at DN2ba
Tal1, Gfi1b, Hhex, and Sfpi1
(PU.1)
Expressed through DN2b stage,
then offa
Lyl1, Kit (growth factor
receptor)
Roles in stem cell self-renewalb Meis1, Tal1, Lyl1, Hhex,
Gfi1b, Erg, Lmo2, and Kit
Roles in lymphomyeloid
progenitor self-renewalb
Bcl11a, Lyl1, Kit, Flt3, and
Hoxa9
T-cell proto-oncogenesb Tal1, Lyl1, Lmo2, Hhex,
Erg, Sfpi1 (if
overexpressed), and Mef2c
aExpression patterns compiled from RNA-seq, quantitative polymer-
ase chain reaction (qPCR), and microarray data (David-Fung et al. 2009;
Yui et al. 2010; Belyaev et al. 2012; Zhang et al. 2012; Mingueneau et al.
2013). The ETP-specific genes are expressed more strongly in samples
taken ex vivo from the thymus than from samples of cells differentiating
in vitro on OP9-DL stroma.
bFor functional role groupings, see references in text.
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to speculate that the Runx-containing repression complex
also might include Bcl11b, although this remains to be
shown. Other phase 1 genes may use quite different si-
lencing machineries.
DEPLOYMENT OF A PHASE 1 REGULATOR:
THE CASE OF PU.1
Is the phase 1 regulatory state actually important for T-
cell development, or simply a “problem” that requires 10
cell cycles to be resolved? We have investigated this ques-
tion by focusing on the phase 1 transcription factor PU.1,
to determine how it may contribute to T-cell development
during the ETP and DN2a stages. This factor poses the
question in particularly simple terms. PU.1 can straight-
forwardly oppose commitment of early T cells, because it
is such a powerful driver of genes used in myeloid and
dendritic cell fates. It has well-documented genome-
wide profiles of target gene binding in different non-T
contexts (Ghisletti et al. 2010; Heinz et al. 2010; Pham
et al. 2013). Interestingly however, despite its limited role
in T-cell precursors, PU.1 can have T-lineage-specific tar-
gets as well. In ETP, DN2a, and DN2b cells, we find PU.1
binding a distinctive pattern of sites across the genome
that differ significantly from the patterns it occupies in
macrophage, B, and pre-pro-B-cell nuclei. The differences
include preferential recruitment to T-lineage enriched
sites as well as exclusion from T-lineage closed sites
(Zhang et al. 2012). This suggests that PU.1 participates
not only in priming the cells for diversion to non-T fates,
but also in some functions that are intrinsic to the T-cell
program.
Such functions can be suspected because PU.1 is actu-
ally required for early T-cell development. When the PU.1
gene is inactivated by Cre deletion in adults, the pipeline
for T-cell development is emptied, as well as for the de-
velopment of obviously PU.1-expressing cell types like
macrophages, dendritic cells, and B cells (Dakic et al.
2005; Carotta et al. 2010b). Thus, despite its visibility as
a factor that keeps open the door to non-T lineage fates,
this is not the most interesting role it can play in the T-cell
development program as such. What is it doing for the
cells, when it is not threatening them with a shift to a
dendritic cell or macrophage identity?
We do know that PU.1 impacts on gene expression are
highly dependent on the status of Notch signaling within
the cells, and Notch signals may help to shape these oc-
cupancy profiles. When Notch signals are withdrawn,
PU.1 can harshly down-regulate numerous T-cell genes
and activate a myeloid program, whereas in the presence
of Notch signaling, PU.1 has different and more limited
effects (Franco et al. 2006; Laiosa et al. 2006; Del Real
and Rothenberg 2013). Despite its high levels in ETP
stage cells, PU.1 does not block the onset of GATA-3
(or TCF-1) expression in response to Notch signals.
Thus, over the next cell cycles if Notch signaling is sus-
tained, PU.1 activity is exerted in a time course overlap-
ping with that of the T-cell factors. PU.1-binding
occupancy is preferentially correlated with positive tran-
scriptional activity of the linked genes, in early T-lineage
cells generally (Zhang et al. 2012). Indeed, it is found
associated with promoters and/or histone-marked distal
regions of a large fraction of the genes that are expressed
during the stages when it is present. At many phase 1 gene
loci, the eventual loss of PU.1 binding as Sfpi1 turns off is
followed by a deposition of repressive chromatin marks at
the previously bound site. Thus, its binding at these sites in
Notch-signaled early T cells is at least permissive and
perhaps stimulatory for gene expression.
PU.1 TARGETS AND THE SEARCH FOR
PHASE 1 REGULATORY FUNCTIONS
A particularly interesting possibility is that the strong,
clean pattern of PU.1-binding sites across the genome of
early T cells can lead us to previously undiscovered genes
that play crucial roles in the poorly understood phase 1
period of T-cell development. Two aspects of phase 1
gene function would be most interesting to determine.
First, population dynamics analysis implies that at least
half of the total number of cell divisions that postnatal T-
cell precursors undergo in the thymus occur in DN1 and
DN2a cells before commitment (Petrie and Zuniga-
Pflucker 2007; Manesso et al. 2013). Thus, “under the
radar” of TCR-dependent proliferation pathways, there is
another entire system that builds the T-cell precursor pool
before TCR gene rearrangement and before commitment.
The genes that support this process are still poorly charac-
terized. Second, there are developmentally regulated tim-
ing functionsthatdetermine howlongphase 1can continue
(David-Fung et al. 2006). In the fetal thymus, phase 1 is a
brief transitory period of few cell cycles, with ETP-pheno-
type cells that have already turned on many DN2-stage
genes on an accelerated schedule (Belyaev et al. 2012).
In contrast, the adult ETP population shows little if any
anticipation of DN2/DN3 gene expression, and in adults
the time spent in ETP and DN2 stages is substantially lon-
ger with a greatly increased number of cell cycles (Lu et al.
2005). Some of the phase 1 genes may therefore determine
the extent of thymic population expansion by controlling
the delay of T-lineage commitment. A role in maintenance
of such genes could explain why PU.1 is important in early
T cells.
There is a long step, however, between showing that
PU.1 binds to a promoter or a nonpromoter element of a
gene and showing that PU.1 is responsible for the regu-
lation of that gene. PU.1 binds to thousands of sites in
these early T cells, at promoters, intronic sites, and inter-
genic sites, and although many of them are also sites of
“accessible” or “active” histone marking, the participa-
tion of PU.1 itself at these sites may be functionally ir-
relevant in many cases. Even though genes linked to
PU.1-binding sites are usually being expressed while
PU.1 binds, most of them are neither increased nor de-
creased in expression subsequently when PU.1 levels
drop more than 10-fold. Therefore, additional methods
are needed to identify the regulatory functions for which
PU.1 is directly responsible.
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Classical gain-of-function approaches have yielded
several positively regulated PU.1 targets encoding tran-
scription factors that could play roles within the phase 1 T-
cell program. These includeBcl11a and Lyl1 as well as the
very early ETP genes, Lmo2 and Mef2c (Del Real and
Rothenberg 2013; A Champhekar and EV Rothenberg,
unpubl.). Adding PU.1 to DN2a/2b cells, which have
already begun to turn these genes off, can boost their
expression back to ETP levels or higher. Flt3, which is
an important cytokine receptor for prethymic cells and
thymus-settling precursors, also requires PU.1 for its ex-
pression (Carotta et al. 2010a) (A Champhekar and EV
Rothenberg, unpubl.). However, to show whether all these
genes are normally regulated by PU.1 at its natural phase 1
levels of expression, it is necessary to show what happens
to them when PU.1 is taken away. Precisely because PU.1
is critical for the survival of these earliest T-cell precur-
sors, it is very difficult to isolate them after deleting PU.1,
to evaluate the effects on phase 1-specific genes. Even
when PU.1 is deleted conditionally at the ETP stage, the
population that survives is highly enriched for cells that
have escaped complete deletion, so that effects are weak
(A Champhekar, unpubl.). To go beyond the limited can-
didate-gene approach to identify the most important PU.1
targets, therefore, it has been important to devise a strat-
egy that can be applied synchronously, and with high
penetrance, to wipe out PU.1 activity in phase 1 cells
quickly enough to monitor the effects before the cells die.
We have found that PU.1 dominant negatives can be
used in gain-of-function experiments as a powerful com-
ponent of such a strategy (A Champhekar, unpubl.). We
have tested several variants of PU.1 dominant negatives,
the most powerful of which delete all but the PU.1 Ets
family DNA-binding domain (Kueh et al. 2013) or con-
vert a truncated PU.1 Ets domain-only molecule into an
obligate repressor by attaching the repression domain
fromDrosophilaEngrailed (AChamphekar and EV Roth-
enberg, unpubl.). Dominant-negative PU.1 antagonizes
the macrophage gene expression programs driven by en-
dogenous PU.1 in myeloid precursors (Kueh et al. 2013),
and these constructs are specific enough to be innocuous
in a T-lineage cell line immortalized at the DN3 stage,
which uses multiple other Ets family transcription factors
but not PU.1 any longer (A Champhekar and EV Rothen-
berg, unpubl.). Even so, they have strong effects within
24 h in normal early T cells which do use PU.1. Two
aspects of the results from forced expression of PU.1-en-
grailed are particularly interesting. First, dominant-nega-
tive transduction can be coupled with genome-wide
transcriptome analysis to identify new PU.1 target genes.
Second, the results give some insight into the role of PU.1
as a factor controlling T-lineage developmental progres-
sion timing itself.
Within 24 h of transfecting the PU.1 dominant nega-
tives into DN2a/2b T-cell precursors, RNA-seq analysis
registers greater than twofold changes in expression of
about 1000 genes, about equally divided between increas-
es and decreases in expression. Note that this strategy only
predicts the genes repressed by PU.1-engrailed to be direct
PU.1 targets; this version of a PU.1 dominant negative
should repress genes that natural PU.1 either activates or
represses, alike. The genes repressed by PU.1 engrailed are
particularly enriched for genes with strong natural PU.1
binding occupancy around them in ETP and DN2a stages,
suggesting that the effect depends on direct engagement
with high-quality PU.1 sites (Fig. 4, top). The repression is
clearly selective for certain binding targets and not others,
suggesting that repression occurs only when the dominant
negative is recruited to a functionally important cis-regu-
latory element, not just any PU.1 occupancy site in the
genome or even any PU.1 occupancy at a promoter.
Thus this search strategy winnows out genes which are
highly sensitive to PU.1. Even better selection emerges
by filtering PU.1-engrailed repressed genes according to
their natural regulation in vivo as PU.1 is turned off (Fig. 4,
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Figure 4. A dominant-negative PU.1-engrailed fusion protein
construct represses genes that are enriched for natural PU.1
binding targets in early T cells. (Top panel) Genome-wide anal-
ysis of impact of PU.1-engrailed on expression of target genes,
as measured by RNA-seq (dark red symbols; A Champhekar, S
Damle, and EV Rothenberg, unpubl.), plotted against peak lev-
els of endogenous PU.1 binding associated with the same genes
in normal DN1 and DN2a cells (blue symbols; Zhang et al.
2012). The genes shown were selected for .3x up-regulation
(left side) or .3x down-regulation (right side) by PU.1-en-
grailed relative to empty vector, 24 h after transduction, and
are ordered on the x-axis from most up-regulated to most
down-regulated. Note that the genes repressed by PU.1-en-
grailed expression (toward the right side) tend to include genes
linked to stronger PU.1 binding sites in vivo. In contrast, an
equal number of genes are up-regulated in cells forced to express
PU.1-engrailed, but these do not show any enrichment for strong
PU.1 binding, consistent with indirect regulation by PU.1 (A
Champhekar, S Damle, and EV Rothenberg, unpubl.). (Bottom
panel) Venn diagram outlining the strategy for combining dom-
inant-negative perturbation, mapping of natural PU.1 binding
site occupancy, and natural developmental expression patterns
to identify new PU.1 targets in an unbiased way.
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bottom). Multiple genes we have newly identified as PU.1
targets by these combined criteria have turned out to re-
spond to acute PU.1 deletion too, although these genes
include both PU.1-activated and PU.1-repressed genes
(A Champhekar, S Damle, and EV Rothenberg, unpubl.).
The other issue that the dominant-negative strategy has
allowed us to tackle is the way PU.1 intersects with the
control of T-cell developmental progression. We discov-
ered that in fact PU.1 quantitatively damps Notch re-
sponses in a dose-dependent way as long as it is present
in the cells, even though Notch1 itself is expressed and
still capable of turning on its own response targets (Fig.
5). In effect, PU.1 sets a threshold for the level of Notch–
Delta interaction that is required to elicit a given response
(Del Real and Rothenberg 2013). Obtaining a sufficiently
strong Notch response is important in turn to keep PU.1
from acting as a net repressor of multiple additional T-
cell genes, many of which are not otherwise Notch de-
pendent. For example, GATA-3 levels can normally re-
main high in the absence of Notch signals, but PU.1 can
repress GATA-3 in the absence of Notch signaling where-
as it cannot do this while Notch signaling is sustained
(Del Real and Rothenberg 2013). The Notch–PU.1 com-
petition is a dynamic balance that shifts the advantage to
the PU.1-dominated or T-cell differentiation programs
with changing conditions. If PU.1 is deleted from cells
that are progressing from ETP to DN2a stage, in fact the
loss now appears to speed up their developmental pro-
gression. Up to this point, then, is PU.1 acting as a direct
repressor of T-cell differentiation genes?
The obligate repressor strategy reveals that the mecha-
nism is almost certainly indirect. Rather than repressing
the T-cell genes and Notch response genes, the obligate
repressor form of PU.1 instead superactivates them. It can
accelerate the onset of expression of DN2–DN3 stage
genes even back to the ETP stage. Thus, despite viability
problems that eventually overtake them, the cells in
which direct PU.1 target genes are repressed begin to
develop faster. Thus, PU.1 not only controls expression
of a substantial battery of phase 1 regulators and viability
genes; it also activates a molecular brake against prema-
ture T-cell differentiation, a brake which depends on
PU.1 and is ultimately removed (Fig. 5).
CONCLUSION
The evidence reviewed here shows that precursors en-
tering the thymus must traverse two distinct gene regula-
tory networks to become committed to the T-cell pathway
(Fig. 6). The functions one considers integral to mature T
cells are conferred upon them in the second network state,
the commitment and postcommitment phases. Access to
this phase is controlled at least in part by a mechanism
that depends on Bcl11b. However, before this stage the
cells must operate a completely different gene network,
one in which PU.1 plays a role, and one which actively
defers the onset of the committed state. We know that
PU.1’s role in this network includes both viability func-
tions and two kinds of focused antagonism against the T-
cell commitment program—one via damping of Notch
signals and the other via another indirect repressive
mechanism. Importantly, the impacts of the PU.1 domi-
nant negative or acute PU.1 deletion imply that the indi-
rect repressive mechanism is an important timing
controller in normal circumstances (Fig. 6). Thus, the
phase 1 genes maintain a stable deferral of T-cell differ-
entiation until the cumulative feed-forward effects of
Sfpi1
a11lcB3tlF2omL
Notch targets T-cell genes
Lyl1
Repressor?
Hhex
PU.1 Notch signals
Lmo2
Figure 5. A partial gene regulatory network driven by PU.1 in early T-lineage precursors. The figure summarizes representative
linkages from the studies described in the text (Franco et al. 2006; Carotta et al. 2010a; Del Real and Rothenberg 2013; A Champhekar,
S Damle, SL Nutt, S Carotta, and EV Rothenberg, unpubl.). Note that combinatorial effects from PU.1 and Notch on certain targets can
split the expression patterns seen in vivo (e.g., Lyl1 vs. Flt3). Additional phase 1 genes that can be activated by PU.1 in these cells
include Mef2c, Meis1, and many myeloid differentiation genes; however, other genes with “phase 1” expression patterns appear to be
direct negative, not positive, regulatory targets of PU.1 (not shown; A Champhekar, S Damle, SL Nutt, S Carotta, and EV Rothenberg,
unpubl.). The effects depicted are those that survive Notch effects on PU.1 activity itself (Franco et al. 2006; Del Real and Rothenberg
2013). Under these conditions at least, PU.1 appears to damp expression of “T-cell genes” such as Tcf7, Ets1, and Zfpm1 through
an indirect mechanism, based on results with the obligate repressor dominant negative, suggesting the involvement of a PU.1-activated
“Repressor X” function(s) (A Champhekar and EV Rothenberg, unpubl.).
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Notch (cf. Fig. 3) finally induce Bcl11b and other regu-
lators that radically shift the balance to extinguish phase 1
gene expression (Fig. 6). This picture of T-cell develop-
ment, transitioning between two mutually opposed net-
work states, suggests why it is so difficult to use single
“master regulator” candidate genes to amplify T-cell gen-
eration. It explains the significance of the continuity with
stem cell regulatory states. Finally, it suggests that impor-
tant controllers of the scale and homeostatic set points for
T-cell population generation may not necessarily be the
genes we associate with T-cell differentiation, but rather
genes that play their roles during the phase 1 stages, and
then allow themselves to be silenced. This picture could
therefore have clinical application as well, but only with
clear recognition of how effective the cells must be in
shutting down the first network when the time comes to
shift to the second.
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